Harbour BioMed Public Relations
E-mail: pr@harbourbiomed.com
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmceutical Co. Ltd. (SZSE:002422).
Harbour BioMed Public Relations
E-mail: pr@harbourbiomed.com